Requena T, Martín MT, Desongles T, Castillo I, Lorente L, Yébenes M
Análisis transversal de la utilización de antivirales en el tratamiento de la hepatitis B crónica. Estudio EUPTHEA
55 Congreso Nacional de la Sociedad Española de Farmacia Hospitalaria (SEFH). Madrid, España. 19-22 oct 2010
Buti M, Wong J, Casado MA, Esteban R
Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B
J Hepatol. 2009;51:640-6
Casado MA, Brosa M, Buti M
Some oral antivirals are more cost-effective than others for the treatment of chronic hepatitis B
J Hepatol. 2009;51:1087-8
Buti M, Brosa M, Casado MA, Rueda M, Esteban R
Modeling the long-term cost-effectiveness of chronic hepatitis B therapies in Spain
11th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Athens, Greece. 8-11 nov 2008
Deniz B, Buti M, Brosa M, Casado MA, Rueda M, Everhard F, Esteban R
Cost-effectiveness simulation analysis of tenofovir disoproxil fumarate, lamivudine, adefovir dipivoxil and entecavir of HBeaAg negative patients with chronic hepatitis-B in Spain
43rd Annual Meeting of the European Association for the Study of the Liver (EASL). Milan, Italy. 23-27 apr 2008
Buti M, Brosa M, Casado MA, Rueda M, Esteban R
Estimación de la morbilidad, mortalidad y costes asociados a la evolución de la hepatitis crónica B en España
XXXIII Congreso Nacional de la Asociación Española para el Estudio del Hígado (AEEH). Madrid, España. 20-22 feb 2008
Buti M, Brosa M, Casado MA, Rueda M, Esteban R
Estimating the impact of chronic hepatitis B on future liver-related morbility, mortality and cost in Spain
58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, Massachusetts, EEUU. 2-6 nov 2007
Buti M, Casado MA, Esteban R
Evaluating the cost of sustained virologic response in naïve chronic hepatitis C patients treated a la carte
Aliment Pharmacol Ther. 2007;26:705-16
Buti M, Casado MA, Esteban R